Prospective, Randomized Trial of Ticagrelor Versus Prasugrel in Patients With Acute Coronary Syndrome

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 4018 participants.

Also called NCT01944800

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; single masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 4,018 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT01944800
  • EudraCT 2013-002272-40
Other papers using this trial's data
  • Access Route and Clinical Outcomes After Ticagrelor Versus Prasugrel in Patients With Acute Coronary Syndrome Undergoing Invasive Treatment Strategy Cardiovascular revascularization medicine : including molecular interventions, 2022-08 DOI, PubMed 35045943
  • Age- and Weight-Adapted Dose of Prasugrel Versus Standard Dose of Ticagrelor in Patients With Acute Coronary Syndromes : Results From a Randomized Trial Annals of internal medicine, 2020-09-15 DOI, PubMed 32687741
  • Assessment of Impact of Patient Recruitment Volume on Risk Profile, Outcomes, and Treatment Effect in a Randomized Trial of Ticagrelor Versus Prasugrel in Acute Coronary Syndromes Journal of the American Heart Association, 2021-11-16 DOI, PubMed 34779234, PMC8751942 In the PMC Open Access subset under CC BY-NC.
  • Body mass index and efficacy and safety of ticagrelor versus prasugrel in patients with acute coronary syndromes Revista espanola de cardiologia (English ed.), 2022-09 DOI, PubMed 34961732
  • Efficacy and safety of ticagrelor versus prasugrel in smokers and nonsmokers with acute coronary syndromes International journal of cardiology, 2021-09-01 DOI, PubMed 34126130
  • Immature Platelet Fraction Predicts Adverse Events in Patients With Acute Coronary Syndrome: the ISAR-REACT 5 Reticulated Platelet Substudy Arteriosclerosis, thrombosis, and vascular biology, 2023-02 DOI, PubMed 36546322
  • Prior Myocardial Infarction and Treatment Effect of Ticagrelor Versus Prasugrel in Patients With Acute Coronary Syndromes - A Post-hoc Analysis of the ISAR-REACT 5 Trial Journal of the American Heart Association, 2022-12-20 DOI, PubMed 36515247, PMC9798807 In the PMC Open Access subset under CC BY-NC-ND.
  • The effect of a Prasugrel- vs. a Ticagrelor-based strategy on total ischaemic and bleeding events in patients with acute coronary syndromes European heart journal. Cardiovascular pharmacotherapy, 2023-04-10 DOI, PubMed 36434779
  • Ticagrelor or Prasugrel for Patients With Acute Coronary Syndrome Treated With Percutaneous Coronary Intervention: A Prespecified Subgroup Analysis of a Randomized Clinical Trial JAMA cardiology, 2021-10-01 DOI, PubMed 34190967, PMC8246339 Not in the PMC Open Access subset.
  • Ticagrelor or Prasugrel in Patients With Acute Coronary Syndrome and High Bleeding Risk Circulation. Cardiovascular interventions, 2022-10 DOI, PubMed 36256695
  • Ticagrelor or Prasugrel in Patients With Acute Coronary Syndrome in Relation to Estimated Glomerular Filtration Rate JACC. Cardiovascular interventions, 2021-09-13 DOI, PubMed 34446390
  • Ticagrelor or Prasugrel in Patients With Non-ST-Segment Elevation Acute Coronary Syndromes Journal of the American College of Cardiology, 2020-11-24 DOI, PubMed 33213722
  • Ticagrelor or Prasugrel in Patients With ST-Segment-Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention Circulation, 2020-12-15 DOI, PubMed 33115278
  • Ticagrelor or Prasugrel in Patients with Acute Coronary Syndromes The New England journal of medicine, 2019-10-17 DOI, PubMed 31475799
  • Ticagrelor or prasugrel in patients with acute coronary syndrome with off-hour versus on-hour presentation: a subgroup analysis of the ISAR-REACT 5 trial Clinical research in cardiology : official journal of the German Cardiac Society, 2023-04 DOI, PubMed 35789430, PMC10050020 In the PMC Open Access subset under CC BY.
  • Twelve-month clinical outcomes in patients with acute coronary syndrome undergoing complex percutaneous coronary intervention: insights from the ISAR-REACT 5 trial European heart journal. Acute cardiovascular care, 2021-12-18 DOI, PubMed 34468709

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Germany, Italy (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01944800. Randomized; single masking; primary purpose treatment. Start 2013-09-15 (actual); primary completion 2019-07 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Prospective, Randomized Trial of Ticagrelor Versus Prasugrel in Patients With Acute Coronary Syndrome
Acronym
ISAR-REACT 5
Condition
Acute Coronary Syndrome (ACS)
Intervention (Drug)
Ticagrelor
Intervention (Drug)
Prasugrel
Lead sponsor
Deutsches Herzzentrum Muenchen (class: other)
Collaborator
Deutsches Zentrum für Herz-Kreislauf-Forschung (DZHK) (class: other)

Record details

Record id
cardio:ct-nct01944800
Content hash
e4ee8bf123f95ac27bd465324e5dffd9353584ba2021dbe2045a2d1e72f58641